 Early ribavirin treatment respiratory syncytial viral infection high-risk children prospective multicenter study efficacy early ribavirin intervention mild respiratory syncytial virus illness children bronchopulmonary dysplasia congenital heart disease cohort children months age bronchopulmonary dysplasia congenital heart disease Forty-seven infants respiratory syncytial virus infection mild symptoms equal hours duration ribavirin water placebo aerosol hospital home Outcome measures respiratory analog score room air oxygen saturation oxygen flow saturation equal difference age gender family size passive smoking baseline oxygen saturations room air duration symptoms treatment groups days therapy ribavirin rate improvement analog scores equal oxygen requirements oxygen saturation Respiratory scores total hospital days groups Treatment failure children ribavirin group children placebo group nonsignificant difference child assisted ventilation adverse reaction early ribavirin therapy morbidity respiratory syncytial virus infection high-risk young children